SEC Form 4 · accession 0001209191-19-009061
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Feb 8, 2019
Accepted (ET)
Feb 11, 2019 · 5:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 8, 2019 | A | 11,031 | A | — | — | Common Stock | 11,031 | 11,031 | D |
| Restricted Stock UnitsF1,F3 | — | Feb 8, 2019 | A | 35,200 | A | — | — | Common Stock | 35,200 | 35,200 | D |
| Stock Option (right to buy)F4 | $18.13 | Feb 8, 2019 | A | 281,600 | A | — | Feb 7, 2029 | Common Stock | 281,600 | 281,600 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- F250% of the restricted stock units shall vest on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
- F325% of the restricted stock units shall vest on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
- F425% of the shares subject to the option shall vest on February 8, 2020, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.